Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 8/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | NAMPT | P43490 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | STAT5A | P42229 | 1/20 | 0.52 |
| ▸ | STAT5B | P51692 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1067926 | 0.83 | HDAC1 (0.80) | HDAC1HDAC2MEN1KMT2ANPC1 | |
| SCHEMBL1064152 | 0.81 | HDAC1 (0.78) | HDAC1HDAC2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1067423 | 0.81 | HDAC1 (0.76) | HDAC1HDAC2MAPTMEN1KMT2A | |
| SCHEMBL12963125 | 0.80 | HDAC1 (0.69) | HDAC1HDAC2MAPTSMN1; SMN2NPC1 | |
| SCHEMBL12933547 | 0.79 | HDAC1 (0.80) | HDAC1HDAC2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1079414 | 0.79 | HDAC1 (1.00) | HDAC1HDAC2 | |
| SCHEMBL1064299 | 0.79 | HDAC1 (0.77) | HDAC1HDAC2MAPT | |
| SCHEMBL15761731 | 0.79 | MEN1 (0.63) | MAPTMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL30690052 | 0.79 | MEN1 (0.63) | MAPTMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL1064557 | 0.78 | HDAC1 (1.00) | HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868205-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | METHYLGENE, INC. (CA) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | HDAC1 1/4885HDAC2 5/4885MAPT 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.